Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
1(13%)
Results Posted
140%(7 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_3
6
75%
Ph phase_2
1
13%

Phase Distribution

0

Early Stage

1

Mid Stage

6

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
6(85.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(5)
Terminated(2)

Detailed Status

Completed5
Terminated2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
71.4%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (14.3%)
Phase 36 (85.7%)

Trials by Status

recruiting113%
completed563%
terminated225%

Recent Activity

1 active trials
Showing 5 of 8
recruiting

ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar

NCT06997055
terminatedphase_3

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis

NCT02437162
terminatedphase_3

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis

NCT02438787
completedphase_3

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age

NCT02698475
completedphase_3

A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

NCT01550744
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06997055

ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar

Recruiting
NCT02437162Phase 3

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis

Terminated
NCT02438787Phase 3

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis

Terminated
NCT02698475Phase 3

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age

Completed
NCT01550744Phase 3

A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

Completed
NCT01389973Phase 2

A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

Completed
NCT01009086Phase 3

A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis

Completed
NCT01077362Phase 3

A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8